1. Home
  2. VYNE

as 09-05-2025 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.

Founded: 2003 Country:
United States
United States
Employees: N/A City: BRIDGEWATER
Market Cap: 7.9M IPO Year: 2018
Target Price: $8.00 AVG Volume (30 days): 1.9M
Analyst Decision: Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.90 EPS Growth: N/A
52 Week Low/High: $0.29 - $4.30 Next Earning Date: 11-06-2025
Revenue: $476,000 Revenue Growth: -2.06%
Revenue Growth (this year): -4.99% Revenue Growth (next year): -35.71%

VYNE Daily Stock ML Predictions

Share on Social Networks: